OBJECTIVES: Proton pump inhibitor (PPI) use has been identified as a risk factor for hip and vertebral fractures. Evidence supporting a relationship between PPI use and osteoporosis remains scant. Demonstrating that PPIs are associated with accelerated bone mineral density (BMD) loss would provide supportive evidence for a mechanism through which PPIs could increase fracture risk. METHODS: We used the Canadian Multicentre Osteoporosis Study data set, which enrolled a population-based sample of Canadians who underwent BMD testing of the femoral neck, total hip, and lumbar spine (L1-L4) at baseline, and then again at 5 and 10 years. Participants also reported drug use and exposure to risk factors for osteoporosis and fracture. Multivariate linear regression was used to determine the independent association of PPI exposure and baseline BMD, and on change in BMD at 5 and 10 years. RESULTS: In all, 8,340 subjects were included in the baseline analysis, with 4,512 (55%) undergoing year 10 BMD testing. After adjusting for potential confounders, PPI use was associated with significantly lower baseline BMD at the femoral neck and total hip. PPI use was not associated with a significant acceleration in covariate-adjusted BMD loss at any measurement site after 5 and 10 years of follow-up. CONCLUSIONS: PPI users had lower BMD at baseline than PPI non-users, but PPI use over 10 years did not appear to be associated with accelerated BMD loss. The reasons for discordant findings between PPI use at baseline and during follow-up require further study.
OBJECTIVES:Proton pump inhibitor (PPI) use has been identified as a risk factor for hip and vertebral fractures. Evidence supporting a relationship between PPI use and osteoporosis remains scant. Demonstrating that PPIs are associated with accelerated bone mineral density (BMD) loss would provide supportive evidence for a mechanism through which PPIs could increase fracture risk. METHODS: We used the Canadian Multicentre Osteoporosis Study data set, which enrolled a population-based sample of Canadians who underwent BMD testing of the femoral neck, total hip, and lumbar spine (L1-L4) at baseline, and then again at 5 and 10 years. Participants also reported drug use and exposure to risk factors for osteoporosis and fracture. Multivariate linear regression was used to determine the independent association of PPI exposure and baseline BMD, and on change in BMD at 5 and 10 years. RESULTS: In all, 8,340 subjects were included in the baseline analysis, with 4,512 (55%) undergoing year 10 BMD testing. After adjusting for potential confounders, PPI use was associated with significantly lower baseline BMD at the femoral neck and total hip. PPI use was not associated with a significant acceleration in covariate-adjusted BMD loss at any measurement site after 5 and 10 years of follow-up. CONCLUSIONS: PPI users had lower BMD at baseline than PPI non-users, but PPI use over 10 years did not appear to be associated with accelerated BMD loss. The reasons for discordant findings between PPI use at baseline and during follow-up require further study.
Authors: Shelly L Gray; Andrea Z LaCroix; Joseph Larson; John Robbins; Jane A Cauley; JoAnn E Manson; Zhao Chen Journal: Arch Intern Med Date: 2010-05-10
Authors: Matthew J Wright; Rebecca R Sullivan; Erin Gaffney-Stomberg; Donna M Caseria; Kimberly O O'Brien; Deborah D Proctor; Christine A Simpson; Jane E Kerstetter; Karl L Insogna Journal: J Bone Miner Res Date: 2010-10 Impact factor: 6.741
Authors: N D Yeomans; Z Tulassay; L Juhász; I Rácz; J M Howard; C J van Rensburg; A J Swannell; C J Hawkey Journal: N Engl J Med Date: 1998-03-12 Impact factor: 91.245
Authors: C J Hawkey; J A Karrasch; L Szczepañski; D G Walker; A Barkun; A J Swannell; N D Yeomans Journal: N Engl J Med Date: 1998-03-12 Impact factor: 91.245
Authors: David N Juurlink; Tara Gomes; Dennis T Ko; Paul E Szmitko; Peter C Austin; Jack V Tu; David A Henry; Alex Kopp; Muhammad M Mamdani Journal: CMAJ Date: 2009-01-28 Impact factor: 8.262
Authors: Thorsten Schinke; Arndt F Schilling; Anke Baranowsky; Sebastian Seitz; Robert P Marshall; Tilman Linn; Michael Blaeker; Antje K Huebner; Ansgar Schulz; Ronald Simon; Matthias Gebauer; Matthias Priemel; Uwe Kornak; Sandra Perkovic; Florian Barvencik; F Timo Beil; Andrea Del Fattore; Annalisa Frattini; Thomas Streichert; Klaus Pueschel; Anna Villa; Klaus-Michael Debatin; Johannes M Rueger; Anna Teti; Jozef Zustin; Guido Sauter; Michael Amling Journal: Nat Med Date: 2009-06 Impact factor: 53.440
Authors: Christian Roux; Karine Briot; Laure Gossec; Sami Kolta; Tilo Blenk; Dieter Felsenberg; David M Reid; Richard Eastell; Claus C Glüer Journal: Calcif Tissue Int Date: 2008-11-21 Impact factor: 4.333
Authors: Daniel H Solomon; Susan J Diem; Kristine Ruppert; Yin Juan Lian; Chih-Chin Liu; Alyssa Wohlfart; Gail A Greendale; Joel S Finkelstein Journal: J Bone Miner Res Date: 2015-02 Impact factor: 6.741
Authors: Daniel E Freedberg; Esi S Lamousé-Smith; Jenifer R Lightdale; Zhezhen Jin; Yu-Xiao Yang; Julian A Abrams Journal: Clin Infect Dis Date: 2015-06-09 Impact factor: 9.079
Authors: Aimee N Pickering; Megan E Hamm; Alicia Dawdani; Joseph T Hanlon; Carolyn T Thorpe; Walid F Gellad; Thomas R Radomski Journal: J Am Geriatr Soc Date: 2020-02-17 Impact factor: 5.562